Brain and Central Nervous System Tumors Clinical Trial
Official title:
A Phase II Safety Study of Bevacizumab in Patients With Multiple Recurrent or Progressive Malignant Gliomas
Verified date | January 2020 |
Source | Northwestern University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the
growth of tumor cells by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with
recurrent or progressive glioma.
Status | Completed |
Enrollment | 55 |
Est. completion date | May 2009 |
Est. primary completion date | November 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed malignant glioma, including the following: - Glioblastoma multiforme - Gliosarcoma - Anaplastic astrocytoma or anaplastic glioma - Malignant glioma not otherwise specified - Evidence of tumor recurrence or progression by MRI or CT scan with contrast - CT scan or MRI must be performed = 96 hours post-operatively (= 2 weeks prior to study registration) or 4-6 weeks post-operatively to assess residual disease in patients who have undergone recent resection of recurrent or progressive tumor - Steroid dosage must have been stable for = 5 days - Failed = 1 prior systemic treatment with chemotherapy or biologic agents (excluding polifeprosan 20 with carmustine implant [Gliadel wafers]) - Failed prior external-beam radiotherapy - If received prior interstitial brachytherapy or stereotactic radiosurgery, true progressive disease (rather than radiation necrosis) must be confirmed by positron emission tomography, single-photon emission computer tomography with thallium, magnetic resonance (MR) spectroscopy, MR perfusion, or surgical documentation PATIENT CHARACTERISTICS: - Karnofsky performance status 70-100% - Life expectancy > 8 weeks - WBC > 3,000/mm³ - Absolute neutrophil count > 1,500/mm³ - Platelet count > 100,000/mm³ - Hemoglobin > 10 g/dL (transfusion allowed) - SGOT and SGPT < 1.5 times upper limit of normal (ULN) - Bilirubin < 1.5 times ULN - Creatinine < 1.5 mg/dL - Blood pressure = 150/100 mm Hg - No unstable angina - No New York Heart Association class II-IV congestive heart failure - No stroke or myocardial infarction within the past 6 months - No clinically significant peripheral vascular disease - No evidence of bleeding diathesis or coagulopathy - Urine protein:creatinine ratio < 1.0 - No significant medical illness that would preclude study participation or cannot be adequately controlled with appropriate therapy - No other serious medical illness or infection - No disease that would obscure toxicity or dangerously alter drug metabolism - No significant traumatic injury within the past 28 days - No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months - No serious, nonhealing wound, ulcer, or bone fracture - No history of any other cancer (except nonmelanoma skin cancer or carcinoma in situ of the cervix) unless cancer is in complete remission and patient is off all therapy for that cancer for = 3 years - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: - See Disease Characteristics - More than 4 weeks since prior surgery for recurrent or progressive disease and recovered - More than 28 days since prior major surgical procedure or open biopsy - At least 4 weeks since prior cytotoxic therapy (6 weeks for nitrosoureas) - At least 2 weeks since prior vincristine - At least 3 weeks since prior procarbazine hydrochloride - At least 1 week since prior noncytotoxic agents (e.g., interferon, tamoxifen, thalidomide, or isotretinoin) - Radiosensitizer does not count - At least 4 weeks since prior experimental biologic agents (e.g., epidermal growth factor receptor [EGFR] inhibitors) - More than 7 days since prior minor surgery, such as fine-needle aspirations or core biopsies - No concurrent combination anti-retroviral therapy for HIV-positive patients - No concurrent enzyme-inducing anticonvulsants (EIACs) - Patients on EIACs must switch to nonenzyme-inducing convulsants = 2 weeks prior to study enrollment |
Country | Name | City | State |
---|---|---|---|
United States | Hematology-Oncology Associates of Illinois | Chicago | Illinois |
United States | Robert H. Lurie Comprehensive Cancer Center at Northwestern University | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Northwestern University | National Cancer Institute (NCI) |
United States,
Raizer JJ, Gallot L, Cohn R, et al.: A phase II safety study of bevacizumab in patients with multiple recurrent or progressive malignant gliomas. [Abstract] J Clin Oncol 25 (Suppl 18): A-2079, 94s, 2007.
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety of Treatment | Safety of treatment will be defined by the number of patients that experience grade 3 and 4 adverse events where causal relationship with bevacizumab cannot be completely ruled out. Adverse events will be graded using Common Terminology Criteria for Adverse Events v3.0 (CTCAE) where: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE |
From treatment initiation, throughout treatment and up to 30 days post-treatment, for up to 1 year. | |
Primary | Progression-free Survival at 6 Months | The number of patients experiencing progression free survival (PFS) was calculated at the 6-month time point. | After all patients have surpassed the 6 month post-treatment timepoint | |
Primary | Tumoral Blood Flow Changes | To assess changes in tumoral blood flow based on MR Perfusion and tissue changes by MR spectroscopy. | Before and after treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 | |
Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 | |
Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 |